Zhitong Financial App News, Chinese Merchants Group (600774.SH) released its semi-annual report for 2023. During the reporting period, the company achieved operating income of 701 million yuan, an increase of 0.05% over the same period last year. Net profit belonging to shareholders of listed companies was 48.2084 million yuan, up 13.06% over the same period last year. Net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 36.3092 million yuan, down 5.65% from the same period last year. Basic earnings per share were 0.1634 yuan per share.
The company's pharmaceutical business is mainly for drug research and development, production and sales. The company's pharmaceutical products are selling 97 kinds of drugs, mainly around the digestive system, respiratory system, anti-infection and other areas. The main products include Rabeprazole sodium enteric-coated tablets, Tongqiao rhinitis granules, amoxicillin capsules, pioglitazone hydrochloride tablets, artificial bezoar metronidazole capsules, ammonia cahuangmin capsules and so on. Among them, Rabeprazole sodium enteric-coated tablets are a new generation of proton pump inhibitors, which are mainly used to treat a variety of digestive tract symptoms, such as active duodenal ulcer, benign active gastric ulcer, esophageal reflux and Helicobacter pylori symptoms. Tongqiao rhinitis granule is a kind of modern proprietary Chinese medicine granule for the treatment of chronic rhinitis, allergic rhinitis and nasal congestion. Amoxicillin capsule is a key compound of amoxicillin capsule chemical, which is mainly used to treat infections caused by sensitive strains.